I'm LongbridgeAI, I can summarize articles.Organogenesis (NASDAQ:ORGO) will release Q2 2026 earnings after market close on August 6. Analysts expect EPS of ($0.35) and revenue of $54.27 million. Recent analyst actions include BTIG downgrading to 'neutral' and Truist setting a 'hold' rating with a $3.00 target. Institutional investors like Federated Hermes and BNP Paribas have increased their stakes. The stock currently holds a consensus 'Hold' rating with an average price target of $5.75.
Organogenesis (NASDAQ:ORGO - Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $54.2740 million for the quarter. Interested persons may review the information on the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.
Get Organogenesis alerts:
Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.08). Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%. The company had revenue of $37.23 million for the quarter, compared to the consensus estimate of $43.26 million.
Organogenesis Price Performance
Shares of NASDAQ:ORGO opened at $2.52 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.16 and a current ratio of 3.53. The firm has a fifty day moving average price of $2.47 and a 200 day moving average price of $2.84. Organogenesis has a fifty-two week low of $2.04 and a fifty-two week high of $7.08. The firm has a market cap of $324.27 million, a price-to-earnings ratio of -13.26 and a beta of 1.33.
Analyst Upgrades and Downgrades
Several brokerages have commented on ORGO. BTIG Research cut shares of Organogenesis from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Truist Financial started coverage on Organogenesis in a research report on Thursday, May 28th. They set a "hold" rating and a $3.00 price objective for the company. Wall Street Zen upgraded Organogenesis from a "strong sell" rating to a "sell" rating in a research report on Saturday, June 20th. UBS Group set a $3.00 price target on Organogenesis in a research note on Thursday, May 28th. Finally, Weiss Ratings cut Organogenesis from a "hold (c)" rating to a "sell (d)" rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Organogenesis currently has a consensus rating of "Hold" and an average target price of $5.75.
View Our Latest Research Report on Organogenesis
Hedge Funds Weigh In On Organogenesis
Large investors have recently modified their holdings of the stock. Quarry LP bought a new stake in Organogenesis in the third quarter worth $25,000. Federated Hermes Inc. raised its stake in shares of Organogenesis by 52.8% in the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company's stock valued at $44,000 after acquiring an additional 2,953 shares during the period. Walleye Capital LLC purchased a new stake in shares of Organogenesis in the second quarter valued at $45,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Organogenesis in the 4th quarter worth about $57,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Organogenesis by 57.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company's stock worth $61,000 after acquiring an additional 5,273 shares during the last quarter. Institutional investors own 49.57% of the company's stock.
About Organogenesis
(Get Free Report)Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.
Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.
Read More
- Five stocks we like better than Organogenesis
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Organogenesis Right Now?
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here